Author

Clary B. Clish

Primary ORCID profile (0000-0001-8259-9245 · 42 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Clary B. ClishiD42 papers · Broad Institute

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Amy A. Deik· 1 shared Bridget K. WagneriD· 1 shared Elizaveta S. Leshchiner· 1 shared Haoxin LiiD· 1 shared Jesse S. BoehmiD· 1 shared John Doench· 1 shared John K. Eaton· 1 shared Maria Alimova· 1 shared

Activity by Year

2018-2018 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Amy A. Deik

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

HIF-2α drives an intrinsic vulnerability to ferroptosis in clear cell renal cell carcinoma

Yilong Zou, Michael J. Palte, Amy A. Deik, Haoxin Li, John K. Eaton, Wenyu Wang, Yuen-Yi Tseng, Rebecca Deasy, Maria Alimova, Vlado Dančík, Elizaveta S. Leshchiner, Vasanthi S. Viswanathan, Sabina Signoretti, Toni K. Choueiri, Jesse S. Boehm, , Stuart L. Schreiber

This paper identifies a vulnerability in clear-cell renal cell carcinoma cells to ferroptosis induced by GPX4 inhibition, driven by the HIF-2-HILPDA pathway and PUFA-lipid enrichment.

bioRxiv · Aug 9, 2018 · PreprintCancer Biology